Overall survival in colon cancer patients with different levels of circulating tumor cells and feasibility of enhancing its prognostic value
Open Access
- 2 September 2022
- journal article
- research article
- Published by Tomsk Cancer Research Institute in Siberian journal of oncology
- Vol. 21 (4) , 32-39
Abstract
Development of personalized approaches to diagnosis, treatment and prognosis of colon cancer (CC) still remains challenging. Levels of circulating tumor (CTC) and cancer stem cells (CSC) are promising non-invasive prognostic factors. Our aim was to assess the overall survival (OS) of patients with stage II–IV CC with different levels of CTCs as well as to enhance their prognostic value by additionally determining the level of CD44+ CSCs. Material and methods. The study included 299 patients with stage II–IV CC. All patients underwent surgery followed by adjuvant chemotherapy (FOLFOX). patients with stage IV CC with resectable liver metastases underwent simultaneous resection of the primary tumor and liver metastases, followed by FOLFOX chemotherapy. the proportion of CTCs was evaluated before surgery using Veridex CellSearch™, and the level of CD44+ CSCs was determined in the tissue of the removed tumor by the IHC method. OS was studied in patients with different CTC levels, cumulative OS was calculated by Kaplan–Meier`s method. prognostic algorithm was designed by logistic regression analysis and cox proportional hazards model. Results. OS was found to be lower in patients with higher CTC levels divided into ranges: 0, 1–3, 4–9, ≥10 (χ2=11.59, p=0.009); thus enabling us to use it for prognosis. its prognostic value is enhanced by estimation of CD44+ CSC in tumor. Statistically significant conjugation between CTC and CD44+ ranges was found. an increase in CTC level by 1 range resulted in the increase in the risk of fatal outcome by 1.58 times (р=0.002); the additive increase in CD44+ expression ≥10 % resulted in the increase in the risk of fatal outcome by 7.2 times (pConclusion. The prognostic algorithm for the risk of unfavorable outcome of patients with CC, based on the assessment of CTC and CD44+ CSC levels, was developed.Keywords
This publication has 17 references indexed in Scilit:
- Heterogeneity in Circulating Tumor Cells: The Relevance of the Stem-Cell SubsetCancers, 2019
- CTCs as a prognostic and predictive biomarker for stage II/III Colon Cancer: a companion study to the PePiTA trialBMC Cancer, 2019
- Prognostic value of pre- and post-operative circulating tumor cells detection in colorectal cancer patients treated with curative resection: a prospective cohort study based on ISET deviceCancer Management and Research, 2018
- The significant prognostic value of circulating tumor cells in colorectal cancer: A systematic review and meta-analysisCurrent Problems in Cancer, 2018
- Clonal Heterogeneity and Tumor Evolution: Past, Present, and the FutureCell, 2017
- Detection of circulating tumor cells with CK20 RT-PCR is an independent negative prognostic marker in colon cancer patients – a prospective studyBMC Cancer, 2017
- Circulating tumour cells from patients with colorectal cancer have cancer stem cell hallmarks in ex vivo cultureGut, 2016
- Circulating Tumor Cell Count Correlates with Colorectal Neoplasm Progression and Is a Prognostic Marker for Distant Metastasis in Non-Metastatic PatientsScientific Reports, 2016
- Gene expression profiling of circulating tumor cells and peripheral blood mononuclear cells from breast cancer patientsOncoImmunology, 2016
- Tumour budding in colorectal cancer: what do we know and what can we do?Virchows Archiv, 2015